ClinicalTrials.gg
Active, not recruitingNCT04428723Updated Feb 6, 2026

Mechanisms of Hypoglycemia in Patients Without Diabetes

An observational study in Hypoglycemia, sponsored by Joslin Diabetes Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Joslin Diabetes Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
33
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Hypoglycemia by Joslin Diabetes Center — 2 open to participants now, 6 under way, none of them phase 3. Hypoglycemia · Joslin Diabetes Center.

Started
2020
with 2 others
Observational
6 of 15
1 open now
Registered
8th of 15
by date

Among the 15 studies in Hypoglycemia by Joslin Diabetes Center, this one is one of 3 that started in 2020, is one of 6 observational ones, and was the 8th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

2 of the 15 studies in Hypoglycemia by Joslin Diabetes Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypoglycemia by Joslin Diabetes Center, or all of them as a file.
02

Study summary

The goal of this study is to identify physiologic and molecular mechanisms that underlie hypoglycemia in the absence of diabetes (or medications that can cause hypoglycemia) and to investigate potential genetic and microbiome differences which contribute to hypoglycemia. We will test the hypothesis that hypoglycemia in the absence of diabetes is linked to genetic variation or the microbiome, and identify whether additional medical history or diagnoses are enriched in the population of patients with hypoglycemia.

Read the detailed description

Although there are several conditions which have been identified that cause, or contribute to hypoglycemia, diagnosis can be challenging, as the physiologic, and molecular mechanisms are incompletely understood. Additionally, treatment options are relatively limited, and often incompletely effective and/or not well tolerated. Investigating the causative factors and mechanisms of hypoglycemia is important therefore in improving our understanding in order to develop new and more effective approaches to treatment.

The current study aims to:

  1. more fully characterize clinical history and demographics in patients with diverse forms of hypoglycemia by creating and analyzing a patient database;
  2. for a subset of patients, characterize metabolic and hormonal responses to a standard meal;
  3. analyze DNA variants in individuals with hypoglycemia;
  4. analyze differences in the intestinal microbiome in individuals with hypoglycemia.
03

Conditions studied

  • Hypoglycemia

Browse trials for

Keywords

  • Microbiome
  • DNA
  • Hormones
  • Genetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

3 groups: (1) patients with hypoglycemia, but without a history of bariatric or other gastrointestinal surgery, recruited from the Joslin Hypoglycemia Clinic, (2) patients with hypoglycemia and history of upper gastrointestinal surgery, recruited from the Joslin Hypoglycemia Clinic,(3) controls without hypoglycemia or surgery, recruited by local advertisement or from family members of patients with hypoglycemia. We plan to enroll patients with hypoglycemia continuously over the next 5 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For hypoglycemia group without a history of bariatric surgery: Males or females diagnosed with hypoglycemia with prior episodes of neuroglycopenia.
  2. For hypoglycemia group with history of upper gastrointestinal surgery: Males or females diagnosed with ongoing hypoglycemia with prior episodes of neuroglycopenia.
  3. For non-surgical controls only: Males or females with no history of upper gastrointestinal surgery and no history of hypoglycemia or diabetes.
  4. Age 18-70 years of age, inclusive, at screening.
  5. Willingness to provide and attend one study visit, with option to attend a second visit with mixed meal test, and follow all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Active treatment with any diabetes medications except for acarbose;
  2. Known insulinoma, gastrinoma, or other neuroendocrine tumor;

Additional exclusion criteria for those participating in optional Visit 2 (meal testing):

  1. Chronic kidney disease stage 4 or 5 (including end-stage renal disease);
  2. Hepatic disease, including serum (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the ; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum > 2.0;
  3. Congestive heart failure, New York Hear Association () class II, III or IV;
  4. History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use;
  5. History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia;
  6. Concurrent administration of β-blocker therapy;
  7. History of a cerebrovascular accident;
  8. Seizure disorder (other than with suspect or documented hypoglycemia);
  9. Active , except basal cell or squamous cell skin cancers;
  10. Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);
  11. Major surgical operation within 30 days prior to screening;
  12. Hematocrit \< 33% (women) or \<36% (men);
  13. Bleeding disorder, treatment with warfarin, or count \<50,000;
  14. Blood donation (1 pint of whole blood) within the past 2 months;
  15. Active alcohol abuse or substance abuse;
  16. Current administration of oral or parenteral ;
  17. Pregnancy and/ or Lactation: For women of : there is a requirement for a negative urine pregnancy test and for agreement to use during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
  18. Use of an drug within 30 days prior to screening.

There will be no involvement of special vulnerable populations such as fetuses, neonates, pregnant women, children, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
33 participants (actual)
Target follow-up
3 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hypoglycemia, no upper gastrointestinal (GI) surgery

    Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes

    Other: Entry of demographic and medical history data into a deidentified database · Genetic: Blood sample for DNA analysis · Diagnostic Test: Stool sample for microbiome analysis · Diagnostic Test: Mixed meal tolerance test · Diagnostic Test: Continuous glucose monitoring · Diagnostic Test: activity monitor

  • Hypoglycemia, with history of upper GI surgery

    Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery

    Other: Entry of demographic and medical history data into a deidentified database · Genetic: Blood sample for DNA analysis · Diagnostic Test: Stool sample for microbiome analysis · Diagnostic Test: Mixed meal tolerance test · Diagnostic Test: Continuous glucose monitoring · Diagnostic Test: activity monitor

  • Controls, without hypoglycemia or upper GI surgery

    Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.

    Other: Entry of demographic and medical history data into a deidentified database · Genetic: Blood sample for DNA analysis · Diagnostic Test: Stool sample for microbiome analysis · Diagnostic Test: Mixed meal tolerance test · Diagnostic Test: Continuous glucose monitoring · Diagnostic Test: activity monitor

Interventions

  • OtherEntry of demographic and medical history data into a deidentified database

    Entry into repository for analysis.

  • GeneticBlood sample for DNA analysis

    Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.

  • Diagnostic testStool sample for microbiome analysis

    Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.

  • Diagnostic testMixed meal tolerance test

    For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.

    Also known as: Meal Testing

  • Diagnostic testContinuous glucose monitoring

    A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.

  • Diagnostic testactivity monitor

    The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.

06

What researchers measure

Primary outcomes

  1. Entry of medical history data into a deidentified database.

    Medical history data will be entered into RedCap for analysis.

    Time frame: March 2020 through March 2025

  2. Entry of physical exam data into a deidentified database.

    Pertinent physical exam data will be entered into RedCap for analysis.

    Time frame: March 2020 through March 2025

  3. Entry of laboratory data into a deidentified database.

    Laboratory data will be entered into RedCap for analysis.

    Time frame: March 2020 through March 2025

  4. Entry of demographic data into a deidentified database.

    Demographic data will be entered into RedCap for analysis.

    Time frame: March 2020 through March 2025

  5. Analysis of participant demographics and medical history, comparing the 3 study groups.

    Demographic and medical history data will be summarized in RedCap and compared between groups using ANOVA or chi-square testing, depending on the variable analyzed.

    Time frame: March 2025

  6. Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing patients with hypoglycemia (both surgical and non-surgical) and healthy controls.

    Sequence variants identified during targeted resequencing will be summarized and prevalence will be compared between groups and with population databases. Depending on results of targeted resequencing, additional expanded genotyping may be performed.

    Time frame: March 2025

  7. Analysis of microbiome, comparing study groups.

    Microbiome will be characterized by sequencing to obtain metagenomic data and pathway analysis; all data will be adjusted for multiple comparisons.

    Time frame: March 2025

  8. Analysis of glucose patterns during masked continuous glucose monitoring (CGM), including time in range, time in hypoglycemia, time in hyperglycemia, comparing the study groups.

    For a subset of participants who consent to participate in optional Visit 2, CGM data will be analyzed to assess mean, median, peak, and nadir sensor glucose values, glycemic variability (GV), severity and length of hypoglycemia (% time glucose \<70, \<60, \<54 mg/dL), and number and duration of severe hypoglycemia (sensor glucose \<54, duration \>15 minutes) will be quantified. Metrics will be assessed over 24 hours and during daytime (6 AM to midnight) and nighttime (midnight to 6 AM) independently.

    Time frame: March 2025

  9. Analysis of metabolic responses during mixed meal testing.

    For a subset of participants who consent to participate in optional Visit 2, magnitude of hypoglycemia will be correlated with metabolite levels during meal testing. Metabolites will be measured at set time points after the start of the mixed meal. Linear mixed effects modeling will be utilized to identify group- and time-dependent differences in metabolic responses. Data will be checked to ensure variables conform to assumptions of the analysis. Sensitivity analysis will determine whether missing data are randomly associated with clinical or experimental phenotypes, and assess the impact of missing data on conclusions. The relationship between clinical and metabolic variables will be analyzed using Pearson correlation, and adjusted for multiple comparisons using Benjamini-Hochberg testing.

    Time frame: March 2025

  10. Analysis of hormonal responses during mixed meal testing.

    For a subset of participants who consent to participate in optional Visit 2, magnitude of hypoglycemia will be correlated with hormone levels during meal testing. Counterregulatory hormones will be measured at set time points after the start of the mixed meal. Linear mixed effects modeling will be utilized to identify group- and time-dependent differences in counterregulatory hormone responses. Data will be checked to ensure variables conform to assumptions of the analysis. Sensitivity analysis will determine whether missing data are randomly associated with clinical or experimental phenotypes, and assess the impact of missing data on conclusions. The relationship between clinical and hormonal variables will be analyzed using Pearson correlation, and adjusted for multiple comparisons using Benjamini-Hochberg testing.

    Time frame: March 2025

Secondary outcomes

  1. Relationship between metabolic responses and magnitude of hypoglycemia as determined by CGM.

    This is for a subset of participants (non-surgical hypoglycemia and controls) participating in optional Visit 2. Magnitude of hypoglycemia will be correlated with metabolite levels during meal testing.

    Time frame: March 2025

  2. Relationship between hormonal responses and magnitude of hypoglycemia as determined by CGM.

    This is for a subset of participants (non-surgical hypoglycemia and controls) participating in optional Visit 2. Magnitude of hypoglycemia will be correlated with counterregulatory hormone levels during meal testing.

    Time frame: March 2025

  3. Relationship between metabolic responses and microbiome.

    This is for a subset of participants (non-surgical hypoglycemia and controls) participating in optional Visit 2. Metagenomic data will be correlated with metabolic responses during meal testing.

    Time frame: March 2025

  4. Relationship between hormonal responses and microbiome.

    This is for a subset of participants (non-surgical hypoglycemia and controls) participating in optional Visit 2. Metagenomic data will be correlated with counterregulatory hormone responses during meal testing.

    Time frame: March 2025

Other outcomes

  1. Safety outcome- hyperglycemia and hypoglycemia during the study

    Participants will be closely monitored and glucose levels will be checked regularly at set time points during optional Visit 2. Symptoms of hypoglycemia will also be assessed at set time points during visits, and as needed.

    Time frame: March 2025

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified participant data may be shared with other researchers with permission of local institutional review boards.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 months after publication of study results.

Access criteria: Data will be shared with academic investigators with approval of local institutional review boards.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 11, 2020
StartActual
Aug 11, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428723
Lead sponsor
Joslin Diabetes Center
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Aug 11, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Mary Elizabeth Patti, MD
principal investigator · Joslin Diabetes Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion